Palisades Park
Palisades Park
Palisades Park, New Jersey, United States8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis | non-infectious anterior uveitis | Recruiting | Phase 2 | 2026-07-28 | NCT07285070 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-05-18 | NCT06996080 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-05-18 | NCT06990399 | |
| Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device. | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Parkinson disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, dementia, disease, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, psychiatric disorder, synucleinopathy, tauopathy | Not yet recruiting | Early phase 1 | 2026-03-10 | NCT07214974 | |
| A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis | neurotrophic keratopathy | Recruiting | Phase 1 / Phase 2 | 2026-02-27 | NCT06999733 | |
| A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis | eye disorder, intermediate uveitis, panuveitis, posterior uveitis, uveal disorder, uveitis | Active, not recruiting | Phase 3 | 2026-01-12 | NCT06431373 | |
| Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 | neurotrophic keratopathy | Recruiting | Phase 3 | 2025-12-23 | NCT05555589 | |
| A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED | Persistent Corneal Epithelial Defect | Recruiting | Phase 2 | 2025-07-24 | NCT05966493 |